1SCHNEIDER M. Characteristics of SonoVue trade mark[J]. Echocardiography,1999, 16 (7Pt2): 743-746.
2MOREL D R,SCHWIEGER I,HOHN L,et al. Human pharmcokinetics and safety evaluation of SonoVue, a new contrast agent for ultrasound imaging[J]. Invest Radiol,2000,35(1): 80-85.
3BOKOR D,CHAMBERS J B,REES P J,et al.Clinical safety of SonoVue, a new contrast agent for ultrasound imaging, in healthy volunteers and in patients with chronic obstructive pulmonary disease[J]. Invest Radiol,2001,36(2):104-109.
4NANDA N C,WISTRAN D C,KARLSBERG R P,et al. Multicenter evaluation of SonoVue for improved endocardial border delineation[J]. Echocardiography,2002,19(1):27-36.
5BOKOR D. Diagnostic efficacy of SonoVue[J]. J Am Coll Cardiol, 2000,86(4A):19G-24G.
6MASUGATA H,LAFITTE S,PETERS B,et al. Comparison of real-time and intermittent triggered myocardial contrast echocardiography for quantification of coronary stenosis severity and transmural perfusion gradient[J]. Circulation, 2001,104(13):1550-1556.
7JANARDHANAN R,SENIOR R. Accuracy of dipyridamole myocardial contrast echo- cardiography for the detection of residual stenosis of the infarct-related artery and multivessel disease early after acute myocardial infarction[J]. J Am Coll Cardiol,2004,43(12):2247-2252.
8LAFITTE S,HIGASHIYAMA A,MASUGATA H,et al. Contrast echocardiography can assess risk area and infarct size during coronary occlusion and reperfusion: experimental validation[J]. J Am Coll Cardiol,2002,39(9):1546-1554.
9SENIOR R,KAUL S,SOMAN P,et al. Power doppler harmonic imaging: a feasibility study of a new technique for the assessment of myocardial perfusion[J]. Am Heart J,2000, 139(2 Pt1):245-251.
10LINDNER J R,VILLANUEVA F S,DENT J M,et al. Assessment of resting perfusion with myocardial contrast echocardiography: theoretical and practical considerations[J]. Am Heart J, 2000,139(2 Pt 1):231-240.
